옵션 체인은 다양한 행사가격과 만기일에 대한 Kiniksa Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Kiniksa Pharmaceuticals에 대한 시장 심리를 평가합니다..

Kiniksa Pharmaceuticals (NASDAQ:KNSA) 주식, 옵션 체인

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

PonyAIFremont,,Ca,,Usa,-,Feb,28,,2020:,Autonomous,Driving,Startup

Equities

Mid Cap

News

Movers

CGON

FTDR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRTC

KNSA

MTSR

PONY

PRDO

포니AI·힘스핸허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일) 오디티 테크, 멧세라, CG 온콜로지, 키닉사 파마슈티컬스, 킹소프트, 프론트도어, ATI, 퍼도세오, 아이리듬

포니AI·힘스앤허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일)

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals International PLC

Cantor Fitzgerald analyst Matthew Prisco downgrades Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) from Overweight to Neutral and lowers the price target from $250 to $135.

Downgrades

Price Target

Analyst Ratings

ONTO

Cantor Fitzgerald Downgrades Onto Innovation to Neutral, Lowers Price Target to $135

Ladenburg Thalmann analyst Jeff Cohen initiates coverage on NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) with a Buy rating and announces Price Target of $1.45.

Initiation

NMTC

Ladenburg Thalmann Initiates Coverage On NeuroOne Medical Tech with Buy Rating, Announces Price Target of $1.45

Benchmark analyst Fawne Jiang initiates coverage on Marti Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MRT#AMEX">MRT</a>) with a Buy rating and announces Price Target of $5.

Benchmark Initiates Coverage On Marti Technologies with Buy Rating, Announces Price Target of $5

<ul>
<li>Binding strategic alliance with KBR (NYSE: KBR), a world-leading engineering group and global technology licensor set to supercharge Hazer's commercialisation strategy</li>
<li>Hazer is KBR's exclusive partner for marketing and licensing of methane pyrolysis technology</li>
<li>Clear revenue visibility targeting multiple license deals within 6 years, materially derisking Hazer's business plan</li>
<li>Capital-lite licensing model maintained; KBR A$3million work program contribution preserves Hazer's robust funding position</li>
<li>Strengthens Hazer's market penetration into high-growth market segments of ammonia and methanol, and regions including North America and Middle East</li>
</ul>
PERTH, Australia, May 05, 2025 (GLOBE NEWSWIRE) -- &nbsp;Hazer Group Ltd ("Hazer" or "the Company") (ASX: HZR) is pleased to announce it has entered into a binding Alliance Agreement (the "Alliance") with Kellogg Brown and Root LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>, "KBR"))) a global leader in technology and engineering solutions, for the commercial deployment and licensing of Hazer's proprietary methane pyrolysis technology.

Hazer Group Enters Into Binding Alliance Agreement With Kellogg Brown And Root For Commercial Deployment And Licensing Of Hazer's Proprietary Methane Pyrolysis Technology

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA –
Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced&nbsp;that the U.S. Food and Drug Administration&nbsp;(FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy.
"Receiving the FDA's Fast Track Designation for ATH434, alongside the Orphan Drug Designation we have already received, underscores the promise of this novel agent to address the urgent need for a disease modifying therapy for individuals with MSA," said, David Stamler, M.D., Chief Executive Officer of Alterity. "This designation reinforces the potential of ATH434 as demonstrated by recent scientific findings related to its mechanism of action and the robust and clinically meaningful efficacy from our double-blind Phase 2 clinical trial. Importantly, the Fast Track designation provides us the opportunity to interact with the FDA more frequently on the advancement of ATH434, potentially accelerating its development path and approval.&nbsp;We look forward to leveraging the Fast Track designation to bring this promising treatment to patients as quickly as possible."
About FDA Fast Track Designation The Fast Track Designation is intended to facilitate and expedite the development and review of new drugs for serious conditions with unmet medical needs, such as MSA. Fast Track designation for a drug candidate confers some or all of the following benefits:
<ul>
<li>Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met</li>
<li>Opportunities for more frequent and early communication with the FDA throughout the development process</li>
<li>Rolling review for the future New Drug Application (NDA) that allows the FDA to begin reviewing sections of an application as they are completed, rather than waiting for the full application. &nbsp;</li>
</ul>
Fast Track eligibility requires demonstration of the potential for clinically meaningful benefits, which can include the mechanism of action, preclinical studies, or data from patient studies. Alterity's previous interactions with the FDA indicated that the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I scale is considered a clinically meaningful endpoint for MSA. Alterity's Fast Track application included <a href="https://www.globenewswire.com/Tracker?data=AVJr6dRYvWxgJaVzHaXt6n5btyZK5tV-2NBu9uCngJU1KefIsO96YuZVriP6JO1ZNOioy-CFm6RT9jMmFdsHguBqyemANNxfzk9pDJS2cyGtk8VSHjsJ06yq3a6uYw2nzBNNL8DsL1vNjTPpHasLmwXaeLMxmzcR00vMinc7NywtUI46D3JYUT2UaKpUwsE3jSdRU0xoT4YJDQV4QjNrnEJYEmKIVCtkgc54OuDy9CkT6OmMi5aXdLUxvJ1n8rzaOTzwGBCdqGqq0fPnx_xpn17GUT8ysYXOP7lm02yygZ1jf_LTc8XcgV01zaoKoEqpbFizz5EppPPCIhbHr-7O3V8wbFpYX4ZiunNsOGj31I-0BvqSkO8rg242Kpfr1em2d_goUU9bfzTgJJgH-JqUmg==">top-line data from the ATH434-201 randomized, double-blind Phase 2 clinical trial</a> which demonstrated efficacy on the modified UMSARS I in addition to preclinical data confirming that ATH434 is a low to moderate affinity iron chaperone.
About ATH434
Alterity's lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models. As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA demonstrated robust clinical efficacy, target engagement on key biomarkers, and a favorable safety profile. A second Phase 2 open-label biomarker trial in patients with more advanced MSA is ongoing. ATH434 has been granted Fast Track Designation by the U.S. FDA, and Orphan Drug Designation by the U.S. FDA and the European Commission for the treatment of MSA.
About ATH434-201 Phase 2 Clinical Trial
The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy, safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or 75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 produced clinically and statistically significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part&nbsp;I, a functional rating scale that assesses disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the positive UMSARS Part I findings including trends in improved motor performance on the Parkinson's Plus rating scale, the Clinical Global Impression of Severity Scale, and the Orthostatic Hypotension Symptom Assessment (a patient reported outcome). Wearable sensor data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect and target engagement relative to placebo. Both dose levels stabilized or reduced iron accumulation in MSA affected brain regions with trends in preservation of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed to ATH434. Additional information on the Phase 2 trial can be found by <a href="https://www.globenewswire.com/Tracker?data=_tHuc6wrDX3ztHSaD_D4H5LIHW0LKVWY7keBMNKQij3GNbBMMmTFCYvmj8LxQnU6mfidifsj2hVp31NQkjHo7K5YRV_vu5Q2u84SJ5AYpNgXfdML6HLYYDNoS13HZCpCaBkug0R7cSJT4EOCR3Pffx2SJp3mrfxNge7an6ZGAqELj2lEyNDZqW7S1j2FatYDHMsijbdnl65R3uZv8ni_i3GdR6M7OJtqz5rfwUh_oG6yPNs6xlec7g2UtgSYo67yaoBuc4DsaFAVfwq4OIqoC-T9x2MEStJFwyPoPwbeDAiNSDLqVr-vJTusCHH--o1emzsCVqmIauQ5XziVDZe8-VarCdnyHCoWtW9wHqxEP6qvjEVS5BnGAUjZlqHv7Juc-cLGNhOYxdfT7iowmTARg6mX_w6VYo8CwhbG7k4S0VFelK2dql5yUZaKZViy3jySkejBTU2QcomvxfU1SmESNPxdtM8rrzS5l8CJZsxE9xY=">ClinicalTrials.gov Identifier: NCT05109091</a>.

Biotech

General

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Announces It Has Been Granted U.S. FDA Fast Track Designation For ATH434 To Treat Multiple System Atrophy

Loop Capital analyst Yun Kim initiates coverage on Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Buy rating and announces Price Target of $140.

OKTA

Loop Capital Initiates Coverage On Okta with Buy Rating, Announces Price Target of $140

Seaport Global analyst Aaron Kessler upgrades Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from Neutral to Buy and announces $165 price target.

Upgrades

RDDT

Seaport Global Upgrades Reddit to Buy, Announces $165 Price Target

GPUS: 190% &#x7C; <a href="https://www.benzinga.com//node/45189955">Hyperscale Data Announces Prelim. Q1 Revenue Surpassing $25M; Sees FY25 Revenue $115M-$125M</a>
&nbsp;
TEVA: 7% &#x7C; <a href="https://www.benzinga.com//node/45190906">Teva Pharmaceuticals shares are trading higher after the company announced FDA Approval for SELARSDI Injection as an interchangeable with the reference biologic Stelara</a>
&nbsp;
WEN: 2% &#x7C; <a href="https://www.benzinga.com//node/45189966">Stephens &amp; Co. Reiterates Equal-Weight on Wendy's, Maintains $14 Price Target</a>

Trading Ideas

GPUS

TEVA

Market-Moving News for May 5th

As of May 5, 2025, two stocks in the consumer discretionary sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">ThredUp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>)</h3>
<ul>
<li>On April 28, Telsey Advisory Group analyst Dana Telsey maintained ThredUp with an Outperform rating and raised the price target from $3 to $6. The company's stock jumped around 57% over the past month and has a 52-week high of $4.58.</li>
<li>RSI Value: 79.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TDUP Price Action: Shares of ThredUp jumped 4% to close at $4.42 on Friday.</li>
<li>Edge Stock Ratings: 99.56 Momentum score with Value at 50.12. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/TDUP"><img loading="lazy" decoding="async" width="477" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05045034/image-34.png" alt="" class="wp-image-900841" style="width:369px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05045034/image-34.png 477w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05045034/image-34-300x108.png 300w" sizes="(max-width: 477px) 100vw, 477px" /></a></figure>
<h3 class="wp-block-heading">Five Below Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)</h3>
<ul>
<li>On May 2, Five Below raised its first-quarter outlook. The company's stock gained around 38% over the past month and<a href="https://www.benzinga.com/quote/FIVE"> has a 52-week high</a> of $147.64.</li>
<li>RSI Value: 71.8</li>
<li>FIVE Price Action: Shares of Five Below gained 11.9% to close at $84.31 on Friday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

FIVE

TDUP

Top 2 Consumer Stocks That May Implode In May

Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) sees Q3 sales of $94.000 million-$97.000 million vs $95.76 million analyst estimate.

Guidance

TWST

Twist Bioscience Sees Q3 Sales $94.000M-$97.000M vs $95.76M Est

Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) affirms FY2025 sales outlook from $53.31 billion-$53.84 billion to $53.31 billion-$53.84 billion vs $53.65 billion estimate.

Tyson Foods expects Sales for 2025 FY to up by flat to 1% YoY.

WIIM

Tyson Foods shares are trading lower after the company reported worse-than-expected Q2 sales results.

Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) ("Stardust Power" or the "Company"), an American developer of battery-grade lithium products, is pleased to announce the execution of a key service agreement with Oklahoma Gas and Electric Company ("OG&amp;E") to develop an electric substation on Stardust Power's site marking a significant milestone in the development of its proposed lithium refinery located within the Southside Industrial Park in Muskogee, Oklahoma. As part of the terms, the cost of engineering, procurement, and construction of the Stardust Power substation will be paid for by a long-term usage commitment by the Company at the facility.
This agreement allows OG&amp;E to further its electrical infrastructure and engineering work needed to supply long-term power to Stardust Power's proposed refinery. Once completed, the refinery will rank among one of the largest lithium refineries in North America. The project is set to play a vital role in strengthening a secure domestic supply chain for battery-grade lithium, an essential material for electric vehicles, energy storage systems, military technologies, and AI applications.
"This agreement reflects not only the incredible support we've received from our utility partners, but also the shared vision for making Oklahoma a national hub for energy infrastructure," said Roshan Pujari, Founder and CEO of Stardust Power. "Reliable and scalable electrical service is a cornerstone of our refinery's operations, and OG&amp;E's partnership ensures we'll have the necessary foundation to power this transformative facility as we build it out and operate it in the future."
The site currently has the capacity to provide construction power, but the new substation will provide operating power for the facility as well as future growth opportunities. Under the agreement, OG&amp;E will initiate site-specific engineering, design and procurement efforts to support the anticipated power load requirements of up to 40 megawatts. The work includes potential upgrades to regional transmission systems and preparation for high-capacity electrical service at the 66-acre site.
"This is a crucial step in bringing power to our site and advancing our project to the next phase," added Chris Celano, Chief Operations Officer, Stardust Power. "It's also a key move toward fulfilling our commitment to job creation and clean energy innovation in Muskogee and Oklahoma."
The refinery project is expected to generate hundreds of well-paying jobs and attract further investment to the region, supporting Oklahoma's growing leadership in clean energy, advanced manufacturing, and critical minerals processing. Stardust Power is working towards its Final Investment Decision ("FID") stage of the project, which when greenlit, will signal the start of detailed design and follow-on construction of the refinery.

Contracts

SDST

Stardust Power And OG&E Enters Infrastructure Agreement To Power One Of North America's Largest Proposed Lithium Refineries Located In Muskogee, Oklahoma

LAMR

Lamar Advertising Acquires Premier Outdoor Media, Adding 200 Billboard Faces Across Northeast Corridor; Deal Terms Not Disclosed

Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) affirms FY2025 sales outlook from $372.00 million-$379.00 million to $372.00 million-$379.00 million vs $376.01 million estimate.

Twist Bioscience Affirms FY2025 Sales Guidance of $372.00M-$379.00M vs $376.01M Est

Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) ("Stardust Power" or the "Company"), an American developer of battery-grade lithium products, is pleased to announce the execution of a key service agreement with Oklahoma Gas and Electric Company ("OG&amp;E") to develop an electric substation on Stardust Power's site marking a significant milestone in the development of its proposed lithium refinery located within the Southside Industrial Park in Muskogee, Oklahoma. As part of the terms, the cost of engineering, procurement, and construction of the Stardust Power substation will be paid for by a long-term usage commitment by the Company at the facility.

Stardust Power Executes Key Service Agreement With OG&E To Develop Electric Substation Within Southside Industrial Park In Muskogee, Oklahoma

JP Morgan analyst John Ivankoe upgrades Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) from Neutral to Overweight and lowers the price target from $17 to $15.

JP Morgan Upgrades Wendy's to Overweight, Lowers Price Target to $15

Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.58) by 13.79 percent. This is a 16.46 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $92.79 million which beat the analyst consensus estimate of $91.99 million by 0.87 percent. This is a 23.23 percent increase over sales of $75.30 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Twist Bioscience Q2 EPS $(0.66) Misses $(0.58) Estimate, Sales $92.79M Beat $91.99M Estimate

Teva Pharmaceuticals shares are trading higher after the company announced FDA Approval for SELARSDI Injection as an interchangeable with the reference biologic Stelara

SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a groundbreaking development in the field of network security. As per the UL Labs report, VaultIC 408 meets FIPS 140-3 requirements, advances NIST certification and strengthens SEALSQ's leadership in secure IoT and smart grid solutions.
SEALSQ's VaultIC 408 Secure Microcontroller (Module Name: VaultIC408 1.2.4, Hardware Version: AT90SO28RS rev A, Firmware Version: 1.2.4.1) has successfully passed NIST FIPS 140-3 testing at Security Level 3 (overall), as confirmed by a Validation Test Report submitted by UL Verification Services Inc. to the Cryptographic Module Validation Program (CMVP). The module's status is listed on the CMVP Modules In Process List at <a href="https://www.globenewswire.com/Tracker?data=cwXzm07zN6WV3agZapM4fI4N84ESI_TTGU8cTk7g5OPRnHvOpzG_AdhwgyqsFfl32Arou9dxt54Im7npX77HOkvRSXMXy1SZHHoF4pzqyMiKZeVOQWI9c95AFOGV0l-fVAmyeanT7NccNU6h7CVw5t6adKVwFRBRZlGHqHZBbw487IcR3qzTpmkgRvorlcgGuzKOjTtQ8_CTAEYXGpFd9NP5EySxOhR0d-kI8o53Y7XFGAYotrsMD_JhRJvs_0pctGEnkKFQ1Lvd9lKSGJ4vOQ==">https://csrc.nist.gov/projects/cryptographic-module-validation-program/modules-in-process</a>. This milestone reinforces SEALSQ's leadership in delivering high-security hardware for Internet of Things (IoT) ecosystems, Smart Grid infrastructure, and other critical applications.
Note: The Cryptographic Module Validation Program (CMVP)&nbsp;Modules In Process and Implementation Under Test (IUT) Lists are provided for information purposes only. Participation on the list is voluntary and is a joint decision by the vendor and Cryptographic Security and Testing (CST) laboratory. Modules are listed alphabetically by vendor name. Posting on the list does not imply guarantee of final validation.
The VaultIC 408 is a state-of-the-art secure microcontroller designed to safeguard connected devices against advanced cyber threats. It integrates hardware-based encryption, authentication, and key management within a tamper-resistant secure element, ensuring robust data integrity and device security. Optimized for IoT and Smart Grid applications, the VaultIC 408 supports low-power, compact designs for smart homes, industrial automation, healthcare, automotive, and digital identity solutions. It secures millions of smart grid hubs for renown device makers supplying for instance the UK's Smart Metering Implementation Programme (SMIP) and is also deployed in smart locks, drones, and satellite IoT platforms.
"UL Labs' report regarding VaultIC 408's FIPS 140-3 Level 3 compliance validates SEALSQ's commitment to delivering cutting-edge secure semiconductors," said Carlos Moreira, CEO of SEALSQ. "This achievement strengthens our ability to provide trusted solutions for global IoT and critical infrastructure markets."
The NIST FIPS 140-3 standard is the global benchmark for cryptographic module security, surpassing FIPS 140-2 with stricter requirements for algorithms, physical security, and operational resilience. It is mandated for U.S. federal agencies and widely adopted in energy, healthcare, defense, and financial sectors []. UL Labs, accredited by the National Voluntary Laboratory Accreditation Program (NVLAP) under Lab Code 100432-0, conducted rigorous testing to ensure compliance. The submitted Validation Test Report positions the VaultIC 408 for final NIST CMVP certification, expected in the coming months, enhancing its credibility for regulated markets.
This inclusion reinforces SEALSQ's position and strategic advancements in the IoT market projected to reach $1.1 trillion by 2030 and the Smart Grid market growing at a 20.8% CAGR through 2032. SEALSQ is poised to meet the rising demand for secure semiconductors.

LAES

SEALSQ's Announces Its VaultIC 408 Meets FIPS 140-3 Requirements

Press Releases

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Health Care

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Comments

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals (KNSA) 옵션

Kiniksa Pharmaceuticals (NASDAQ:KNSA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌